Up-to-date Information on
Waldenström’s macroglobulinemia



The state-of-the-art glossary for Waldenström’s macroglobulinemia.


Zanubrutinib in the glossary for Waldenström's macroglobulinemia

A small molecule second-generation inhibitor of Bruton's tyrosine kinase

Zanubrutinib is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) currently being evaluated in a broad late-stage clinical trials program globally, as a potential monotherapy and in combination with other therapies to treat various B-cell malignancies. Zanubrutinib is in pivotal Phase 2 and Phase 3 trials in several B-cell malignancies including: Waldenstrom’s macroglobulinemia (WM), treatment-naive mantle cell lymphoma (MCL), both front-line and relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), relapsed/refractory follicular lymphoma, marginal zone lymphoma, and diffuse large B-cell lymphoma. Zanubrutinib is not licensed for use in the EU.


Video: Zanubrutinib – Mode of Action

Zanubrutinib - Mode of Action


Glossary overview